Safety and Immunogenicity of a Live-attenuated Vaccine Against Respiratory Syncytial Virus in Elderly Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 10, 2020

Primary Completion Date

March 6, 2021

Study Completion Date

May 26, 2021

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL

CodaVax-RSV

Codon deoptimized, live-attenuated vaccine against RSV delivered intranasally via dropper

BIOLOGICAL

Normal saline

Saline (0.9%) administered via dropper

Trial Locations (1)

Nucleus Network/Q-Pharm, Brisbane